The filings provide a glimpse of the company's struggles. Can cannabinoids pull the business out of the doldrums?
News & Analysis: Amyris
The company filed its annual report for 2018 and gave a brief update on first-half 2019 operations.
An overlooked announcement provides an opportunity for a management team that has lost the trust of investors.
The company hopes new products in development and a reshuffled debt portfolio can deliver long-awaited growth and profits. Investors have heard that before.
Another day, another transaction. Is the synthetic biology pioneer better positioned to execute now?
The business received a small lifeline from one of its largest shareholders.
Shares of the synthetic biology pioneer have risen and fallen by double digits many days in recent weeks.
The company reported poor operating performance in 2018, but has attempted to focus the attention of investors on its future.
The company notified the Securities and Exchange Commission that it couldn't file its annual report on time. It gave three reasons.
AMRS earnings call for the period ending December 31, 2018.